89 related articles for article (PubMed ID: 28702874)
1. The extent and quality of qualitative evidence included in health technology assessments: a review of submissions to NICE and CADTH.
Szabo SM; Hawkins NS; Germeni E
Int J Technol Assess Health Care; 2023 Dec; 40(1):e6. PubMed ID: 38126273
[TBL] [Abstract][Full Text] [Related]
2. Justifying the source of external comparators in single-arm oncology health technology submissions: a review of NICE and PBAC assessments.
Appiah K; Rizzo M; Sarri G; Hernandez L
J Comp Eff Res; 2024 Feb; 13(2):e230140. PubMed ID: 38174576
[No Abstract] [Full Text] [Related]
3. The evolution of the cancer formulary review in Canada: Can centralization improve the use of economic evaluation?
Wranik WD; Gambold L; Hanson N; Levy A
Int J Health Plann Manage; 2017 Apr; 32(2):e232-e260. PubMed ID: 27469429
[TBL] [Abstract][Full Text] [Related]
4. Management of Hospital Formularies in Ontario: Challenges within a Local Health Integration Network.
Burke N; Bowen JM; Troyan S; Jegathisawaran J; Gosse C; Tonkin M; Kagoma S; Goeree R; Holbrook A
Can J Hosp Pharm; 2016; 69(3):187-93. PubMed ID: 27402997
[TBL] [Abstract][Full Text] [Related]
5. The impact of orthopaedic research evidence on health financing in Australia.
Hua M; Myers D; Host L
Health Res Policy Syst; 2018 May; 16(1):36. PubMed ID: 29716606
[TBL] [Abstract][Full Text] [Related]
6. Institutionalizing Health Technology Assessment in South Africa-An Opportunity in National Health Insurance.
Jugathpal J; Parrish A; Jamaloodien K; Blecher M; Daven J
Health Syst Reform; 2023 Dec; 9(3):2327098. PubMed ID: 38715202
[TBL] [Abstract][Full Text] [Related]
7. Hong Kong Hospital Authority resource efficiency evaluation: Via a novel DEA-Malmquist model and Tobit regression model.
Guo H; Zhao Y; Niu T; Tsui KL
PLoS One; 2017; 12(9):e0184211. PubMed ID: 28886087
[TBL] [Abstract][Full Text] [Related]
8. Institutional Priority-Setting for Novel Drugs and Therapeutics: A Qualitative Systematic Review.
Wang DE; Hassanein M; Razvi Y; Shaul RZ; Denburg A
Int J Health Policy Manag; 2024; 13():7494. PubMed ID: 38618836
[TBL] [Abstract][Full Text] [Related]
9. Role of centralized review processes for making reimbursement decisions on new health technologies in Europe.
Stafinski T; Menon D; Davis C; McCabe C
Clinicoecon Outcomes Res; 2011; 3():117-86. PubMed ID: 22046102
[TBL] [Abstract][Full Text] [Related]
10. Deliberative process of health technology reassessment by health technology assessment agency in Korea.
Shin S; Kim Y; Choi J; Park JY;
Int J Technol Assess Health Care; 2024 May; 40(1):e28. PubMed ID: 38738417
[TBL] [Abstract][Full Text] [Related]
11. The use of pharmacoeconomic evidence to support formulary decision making in Saudi Arabia: Methodological recommendations.
Al Aqeel SA; Al-Sultan M
Saudi Pharm J; 2012 Jul; 20(3):187-94. PubMed ID: 23960792
[TBL] [Abstract][Full Text] [Related]
12. Blockchains, Formulary Evaluations and Health Technology Assessment.
Langley PC; Martin RE
Innov Pharm; 2018; 9(4):. PubMed ID: 34007722
[TBL] [Abstract][Full Text] [Related]
13. Value Assessment, Real World Evidence and Fundamental Measurement: Version 3.0 of the Minnesota Formulary Submission Guidelines.
Langley PC
Innov Pharm; 2020; 11(4):. PubMed ID: 34007644
[TBL] [Abstract][Full Text] [Related]
14. 6-STEPPPs: A Modular Tool to Facilitate Clinician Participation in Fair Decisions for Funding New Cancer Drugs.
Browman GP; Manns B; Hagen N; Chambers CR; Simon A; Sinclair S
J Oncol Pract; 2008 Jan; 4(1):2-7. PubMed ID: 20859436
[TBL] [Abstract][Full Text] [Related]
15. The Hong Kong Principles for assessing researchers: Fostering research integrity.
Moher D; Bouter L; Kleinert S; Glasziou P; Sham MH; Barbour V; Coriat AM; Foeger N; Dirnagl U
PLoS Biol; 2020 Jul; 18(7):e3000737. PubMed ID: 32673304
[TBL] [Abstract][Full Text] [Related]
16. Establishment of a children's Drugs and Therapeutics Committee to ensure evidence-based and cost-effective medical treatment for children.
Holst SS; Møller CH; Vermehren C; Trolle S; Hansen B; Kirkedal AK; Christensen HR; Jacobsen T; Mathiasen R; Andersen JÞT; Gade C
Br J Clin Pharmacol; 2024 Feb; 90(2):378-387. PubMed ID: 37879905
[TBL] [Abstract][Full Text] [Related]
17. Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong.
Loong HH; Wong CKH; Leung LKS; Dhankhar P; Insinga RP; Chandwani S; Hsu DC; Lee MYK; Huang M; Pellissier J; Rai A; Achra M; Tan SC
Pharmacoecon Open; 2020 Jun; 4(2):235-247. PubMed ID: 31531842
[TBL] [Abstract][Full Text] [Related]
18. Towards a Transparent, Credible, Evidence-Based Decision-Making Process of New Drug Listing on the Hong Kong Hospital Authority Drug Formulary: Challenges and Suggestions.
Wong CKH; Wu O; Cheung BMY
Appl Health Econ Health Policy; 2018 Feb; 16(1):5-14. PubMed ID: 28702874
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
